METTL3 enhances CRC progression by affecting the expression of Glucose Transporter Type 1, increasing glucose uptake, and activating the mammalian target of rapamycin complex 1 (MTORC1) signaling pathway, which is essential for biosynthesis. The gene discussed is METTL3; the disease is colorectal carcinoma.